The estimated Net Worth of James E Deerfield Mgmt Hif,... is at least $41.6 mil dollars as of 17 February 2021. James Hif owns over 300,000 units of Oncorus stock worth over $41,593 and over the last 4 years James sold ONCR stock worth over $0.
James has made over 2 trades of the Oncorus stock since 2020, according to the Form 4 filled with the SEC. Most recently James bought 300,000 units of ONCR stock worth $5,700,000 on 17 February 2021.
The largest trade James's ever made was buying 1,000,000 units of Oncorus stock on 6 October 2020 worth over $15,000,000. On average, James trades about 650,000 units every 67 days since 2020. As of 17 February 2021 James still owns at least 345,167 units of Oncorus stock.
You can see the complete history of James Hif stock trades at the bottom of the page.
Over the last 4 years, insiders at Oncorus have traded over $1,276,271 worth of Oncorus stock and bought 2,354,001 units worth $35,555,648 . The most active insiders traders include Ansbert Gadicke, Luke Evnin y James E Deerfield Mgmt Hif,.... On average, Oncorus executives and independent directors trade stock every 34 days with the average trade being worth of $15,538. The most recent stock trade was executed by James E Deerfield Mgmt Hif,... on 28 December 2022, trading 336,235 units of ONCR stock currently worth $87,421.
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Oncorus executives and other stock owners filed with the SEC include: